5 Feb 2025director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer bought 700 shares on the open market at $2.49.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
5 Feb 2025director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami bought 700 shares on the open market at $2.49.
3 Jan 2025substantial holder notice● Neutral
SABBY MANAGEMENT, LLC reported a Arcadia Biosciences, Inc. shareholding of 4.90% of votes in a periodic institutional filing.
11 Dec 2024business combination▲ GoodMajor
Arcadia announced an all-stock business combination with Roosevelt Resources, LP, a Texas oil-and-gas exploration and production limited partnership formed in 2011 -- structured as a reverse merger in which Roosevelt's limited partners would end up owning approximately 90% of the combined company and existing Arcadia stockholders just 10%, effectively taking Roosevelt public through Arcadia's Nasdaq shell rather than a conventional biotech/ag transaction.
12 Nov 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.5 million and a net loss of $1.6 million for the period ended 2024-09-30.
12 Nov 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.5 million and a net loss of $1.6 million for the period ended 2024-09-30.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer received a stock option grant for 20,000 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Deborah D Carosella received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Albert D. Bolles received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Lilian Shackelford Murray received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Gregory D Waller received a stock option grant for 10,909 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami received a stock option grant for 20,000 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Kevin Comcowich received a stock option grant for 25,455 shares.
21 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. insider Amy Yoder received a stock option grant for 10,909 shares.
20 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Mark Kawakami bought 700 shares on the open market at $2.06.
20 Aug 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Thomas J. Schaefer bought 700 shares on the open market at $2.06.
13 Aug 2024quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $1.1 million for the period ended 2024-06-30.
13 Aug 2024quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $1.1 million for the period ended 2024-06-30.
18 July 2024director interest notice● Neutral
Mark Kawakami became a Arcadia Biosciences, Inc. Chief Financial Officer and company insider (initial ownership filing).
20 May 2024asset acquisition disposition▼ BadMajor
Arcadia exited its GoodWheat specialty-wheat business, selling the assets to Above Food Corp (through subsidiary Arcadia Wellness) -- and paying Above Food $2 million cash as part of the deal -- in exchange for a $6 million promissory note from Above Food, payable in three annual installments over three years and secured by the purchased assets. The unusual structure (paying cash to divest) suggests GoodWheat's ongoing costs outweighed a clean sale price.
17 May 2024asset acquisition disposition▲ GoodMajor
Arcadia sold and licensed its resistant starch durum wheat trait IP to Pioneer Hi-Bred International (a Corteva subsidiary that had worked on the trait since 2017) for $4 million cash -- monetizing a legacy licensing relationship.
13 May 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $987 thousand and a net loss of $2.4 million for the period ended 2024-03-31.
9 May 2024quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $987 thousand and a net loss of $2.4 million for the period ended 2024-03-31.
14 Feb 2024substantial holder notice● Neutral
Armistice Capital, LLC, Steven Boyd reported a Arcadia Biosciences, Inc. shareholding of 58,315 shares (4.99% of votes) in a periodic institutional filing.
5 Feb 2024director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer bought 700 shares on the open market at $2.06.
9 Nov 2023quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and a net loss of $2.6 million for the period ended 2023-09-30.
9 Nov 2023quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and a net loss of $2.6 million for the period ended 2023-09-30.
10 Aug 2023quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $823 thousand for the period ended 2023-06-30.
10 Aug 2023quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $1.3 million and net income of $823 thousand for the period ended 2023-06-30.
7 Aug 2023director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Thomas J. Schaefer bought 649 shares on the open market at $3.67.